Headinvest LLC Buys 248 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Headinvest LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.9% during the fourth quarter, Holdings Channel reports. The firm owned 1,333 shares of the medical research company’s stock after purchasing an additional 248 shares during the quarter. Headinvest LLC’s holdings in Thermo Fisher Scientific were worth $693,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Stonegate Investment Group LLC increased its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company’s stock valued at $3,531,000 after buying an additional 18 shares during the last quarter. Semus Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company’s stock valued at $245,000 after buying an additional 18 shares during the last quarter. Evernest Financial Advisors LLC increased its holdings in Thermo Fisher Scientific by 4.0% during the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company’s stock valued at $271,000 after buying an additional 20 shares during the last quarter. Proactive Wealth Strategies LLC increased its stake in shares of Thermo Fisher Scientific by 2.7% in the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company’s stock worth $392,000 after purchasing an additional 20 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company’s stock worth $1,189,000 after purchasing an additional 20 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock worth $7,305,942 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Argus reduced their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. UBS Group dropped their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Finally, Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Down 3.8%

Shares of Thermo Fisher Scientific stock opened at $397.89 on Thursday. The firm’s 50 day moving average price is $447.48 and its 200-day moving average price is $507.46. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The company has a market cap of $150.20 billion, a P/E ratio of 24.07, a PEG ratio of 2.99 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.